What is SynAgile?
SynAgile is a pharmaceutical company dedicated to developing novel medicines for patients suffering from Parkinson's disease. At the core of its innovation is the proprietary OraFuse Technology, a groundbreaking non-invasive method for oral drug delivery. This technology aims to improve patient compliance and therapeutic efficacy by enabling precise and convenient administration of medications directly within the mouth. The company's focus on a debilitating neurological condition positions it within a critical area of unmet medical need.
How much funding has SynAgile raised?
SynAgile has raised a total of $19.4M across 2 funding rounds:
Private Equity
$10.4M
Debt
$9M
Private Equity (2017): $10.4M with participation from TAMCAP LLC
Debt (2021): $9M, investors not publicly disclosed
Key Investors in SynAgile
TAMCAP LLC
TAMCAP LLC is identified as a player in the Custom Software & IT Services industry, suggesting a potential strategic interest in technology integration or operational efficiency within SynAgile's pharmaceutical development.
What's next for SynAgile?
The recent major strategic investment signals a pivotal phase for SynAgile, likely enabling the company to accelerate its research and development pipeline, scale manufacturing capabilities, and potentially expand its clinical trial programs. This infusion of capital is expected to drive the advancement of its Parkinson's disease therapies and further validate the OraFuse Technology. SynAgile's trajectory suggests a focus on achieving key regulatory milestones and preparing for broader market penetration, leveraging its enterprise-level backing to solidify its position as a leader in neurodegenerative disease treatment.
See full SynAgile company page
